Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors

被引：0
|
作者：
Castello, A. [1 ]
Rossi, S. [1 ]
Toschi, L. [1 ]
Lopci, E. [1 ]
机构：
[1] Humanitas Clin & Res Hosp, Rozzano, MI, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPS-024
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [31] Dynamic clonality of T cell receptor differentiate atypical progression in NSCLC patients treated with PD-1/PD-L1 inhibitors
    Han, Jiefei
    Wang, Zhijie
    Wang, Yuqi
    Chen, Si
    Bai, Hua
    Duan, Jianchun
    Wang, Jie
    CANCER RESEARCH, 2019, 79 (13)
  • [32] Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC
    Bouhamama, Amine
    Leporq, Benjamin
    Faraz, Khuram
    Foy, Jean-Philippe
    Boussageon, Maxime
    Perol, Maurice
    Ortiz-Cuaran, Sandra
    Ghiringhelli, Francois
    Saintigny, Pierre
    Beuf, Olivier
    Pilleul, Frank
    FRONTIERS IN RADIOLOGY, 2023, 3
  • [33] Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
    Yimin Wang
    Hedong Han
    Fang Zhang
    Tangfeng Lv
    Ping Zhan
    Mingxiang Ye
    Yong Song
    Hongbing Liu
    British Journal of Cancer, 2022, 127 : 948 - 956
  • [34] Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors
    Mota, Jose Mauricio
    Teo, Min Yuen
    Whiting, Karissa
    Li, Han A.
    Regazzi, Ashely M.
    Lee, Chung-Han
    Funt, Samuel A.
    Bajorin, Dean
    Ostrovnaya, Irina
    Iyer, Gopa
    Rosenberg, Jonathan E.
    JOURNAL OF IMMUNOTHERAPY, 2021, 44 (07) : 248 - 253
  • [35] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
  • [36] Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
    Anand, Kartik
    Sahu, Geetanjali
    Burns, Ethan
    Ensor, Allyne
    Ensor, Joe
    Pingali, Sai Ravi
    Subbiah, Vivek
    Iyer, Swaminathan P.
    ESMO OPEN, 2020, 5 (04)
  • [37] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    RESPIROLOGY, 2023, 28 : 99 - 99
  • [38] Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC
    Rothschild, S. I.
    Leger, P.
    Castellanos, E. L.
    Pillai, R. N.
    York, S. J.
    Horn, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors
    Abu Sabbah, Tanja
    Theurer, Sarah
    Baba, Hideo Andreas
    Lueong, Smiths
    Rashidi-Alavijeh, Jassin
    Hilser, Thomas
    Zaun, Yasmin
    Metzenmacher, Martin
    Pogorzelski, Michael
    Virchow, Isabel
    Pretzell, Ina
    Kostbade, Karina
    Treckmann, Jurgen
    Wiesweg, Marcel
    Schuler, Martin
    Kasper, Stefan
    Zaun, Gregor
    EUROPEAN JOURNAL OF CANCER, 2024, 210
  • [40] Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression
    Aguiar Junior, P. N.
    De Mello, R.
    Tadokoro, H.
    Babiker, H. M.
    Lopes, G., Jr.
    ANNALS OF ONCOLOGY, 2016, 27
12345